1Samartin, S & Chandra, RK (2001) Obesity, overnutrition and the immune system. Nutr Res 21, 243–262.
2Flegal, KM, Carroll, MD, Kit, BK, et al. (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307, 491–497.
3Ogden, CL, Carroll, MD, Kit, BK, et al. (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 307, 483–490.
4Berghöfer, A, Pischon, T, Reinhold, T, et al. (2008) Obesity prevalence from a European perspective: a systematic review. BMC Public Health 8, 200.
5Saris, WH & Harper, A (2005) DiOGenes: a multidisciplinary offensive focused on the obesity epidemic. Obes Rev 6, 175–176.
6von Ruesten, A, Steffen, A, Floegel, A, et al. (2011) Trend in obesity prevalence in European adult cohort populations during follow-up since 1996 and their predictions to 2015. PLoS One 6, e27455.
7Kanneganti, T-D & Dixit, VD (2012) Immunological complications of obesity. Nat Immunol 13, 707–712.
8Milner, JJ & Beck, MA (2012) The impact of obesity on the immune response to infection. Proc Nutr Soc 71, 298–306.
9Smith, AG, Sheridan, PA, Harp, JB, et al. (2007) Diet-induced obese mice have increased mortality and altered immune responses when infected with influenza virus. J Nutr 137, 1236–1243.
10Karlsson, EA, Sheridan, PA & Beck, MA (2010) Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol 184, 3127–3133.
11Smith, AG, Sheridan, PA, Tseng, RJ, et al. (2009) Selective impairment in dendritic cell function and altered antigenspecific CD8+ T-cell responses in diet-induced obese mice infected with influenza virus. Immunology 126, 268–279.
12Van Kerkhove, MD, Vandemaele, KA, Shinde, V, et al. (2011) Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 8, e1001053.
13Kwong, JC, Campitelli, MA & Rosella, LC (2011) Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 53, 413–421.
14Falagas, ME & Kompoti, M (2006) Obesity and infection. Lancet Infect Dis 6, 438–446.
15Bercault, N, Boulain, T, Kuteifan, K, et al. (2004) Obesity-related excess mortality rate in an adult intensive care unit: a risk-adjusted matched cohort study. Crit Care Med 32, 998–1003.
16Bochicchio, GV, Joshi, M, Bochicchio, K, et al. (2006) Impact of obesity in the critically ill trauma patient: a prospective study. J Am Coll Surg 203, 533–538.
17Dossett, LA, Dageforde, LA, Swenson, BR, et al. (2009) Obesity and site-specific nosocomial infection risk in the intensive care unit. Surg Infect 10, 137–142.
18Serrano, PE, Khuder, SA & Fath, JJ (2010) Obesity as a risk factor for nosocomial infections in trauma patients. J Am Coll Surg 211, 61–67.
19Cantürk, Z, Cantürk, NZ, Çetinarslan, B, et al. (2003) Nosocomial infections and obesity in surgical patients. Obesity 11, 769–775.
20Potapov, EV, Loebe, M, Anker, S, et al. (2003) Impact of body mass index on outcome in patients after coronary artery bypass grafting with and without valve surgery. Eur Heart J 24, 1933–1941.
21Davenport, DL, Xenos, ES, Hosokawa, P, et al. (2009) The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. J Vasc Surg 49, 140–147.
22Dempsey, PW, Vaidya, SA & Cheng, G (2003) The art of war: innate and adaptive immune responses. Cell Mol Life Sci 60, 2604–2621.
23Zunino, SJ, Parelman, MA, Freytag, TL, et al. (2011) Effects of dietary strawberry powder on blood lipids and inflammatory markers in obese human subjects. Br J Nutr 108, 909–909.
24Hannum, SM (2004) Potential impact of strawberries on human health: a review of the science. Crit Rev Food Sci Nutr 44, 1–17.
25Locksley, RM, Killeen, N & Lenardo, MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501.
26Pfeffer, K (2003) Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 14, 185–191.
27Croft, M (2003) Costimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3, 609–620.
28Guidotti, LG & Chisari, FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Ann Rev Immunol 19, 65–91.
29Dixon, WG, Watson, K, Lunt, M, et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 54, 2368–2376.
30Furst, DE (2010) The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 39, 327–346.
31Kim, SY & Solomon, DH (2010) Tumor necrosis factor blockade and the risk of viral infection. Nat Rev 6, 165–174.
32Galloway, JB, Hyrich, KL, Mercer, LK, et al. (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50, 124–131.
33Atzeni, F, Sarzi-Puttini, P, Botsios, C, et al. (2012) Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 12, 225–229.
34Vykouhal, D & Davies, MG (2011) Vascular biology of metabolic syndrome. J Vasc Surg 54, 819–831.
35Ziccardi, P, Nappo, F, Giugliano, G, et al. (2002) Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105, 804–809.
36Straczkowski, M, Kowalska, I, Nikolajuk, A, et al. (2006) Plasma levels of soluble tumor necrosis factor-a receptors are related to total and LDL-cholesterol in lean, but not obese subjects. Cardiovasc Diabetol 5, 14.
37Beutler, B (2000) Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr Opin Microbiol 3, 23–28.
38Wong, PM, Chugn, SW & Sultzer, BM (2000) Genes, receptors, signals and responses to lipopolysaccharide endotoxin. Scand J Immunol 51, 123–127.
39Sultzer, BM & Goodman, GW (1976) Endotoxin protein: a B-cell mitogen and polyclonal activator of C3H/HeJ lymphocytes. J Exp Med 144, 821–827.
40Morrison, DC, Betz, SJ & Jacobs, DM (1976) Isolation of a lipid A bound polypeptide responsible for “LPS-initiated” mitogenesis of C3H/HeJ spleen cells. J Exp Med 144, 840–846.
41Hirschfeld, M, Ma, Y, Weis, JH, et al. (2000) Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J Immunol 165, 618–622.
42Harty, JT, Tvinnereim, AR & White, DW (2000) CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol 18, 275–308.
43Dumitru, CD, Ceci, JD, Tsatsanis, C, et al. (2000) TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103, 1071–1083.
44Symons, A, Beinke, S & Ley, SC (2006) MAP kinase kinase kinases and innate immunity. Trends Immunol 27, 40–48.
45Ponta, H, Sherman, L & Herrlich, PA (2003) CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 4, 33–45.
46Springer, TA, Dustin, ML, Takashi, KK, et al. (1987) The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Ann Rev Immunol 5, 223–252.
47Proost, P, Wuyts, A & Van Damme, J (1996) Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leuk Biol 59, 67–74.
48Gong, W, Howard, OMZ, Turpin, JA, et al. (1997) Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J Biol Chem 273, 4289–4292.
49Taub, DD, Conlon, K, Lloyd, AR, et al. (1993) Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 260, 355–358.
50Narni-Mancinelli, E, Campisi, L, Bassand, D, et al. (2007) Memory CD8+ T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI+ phagocytes. J Exp Med 9, 2075–2087.
51Scott, A, Weldon, S & Taggart, CC (2011) SLPI and elafin: multifunctional antiproteases of the WFDC family. Biochem Soc Trans 39, 1437–1440.
52Zani, M-L, Tanga, A, Saidi, A, et al. (2011) SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Biochem Soc Trans 39, 1441–1446.
53Martinon, F & Tschopp, J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14, 10–22.
54Sollberger, G, Strittmatter, GE, Kistowska, M, et al. (2012) Caspase-4 is required for activation of inflammasomes. J Immunol 188, 1992–2000.
55Philpott, DJ & Girardin, SE (2004) The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 41, 1099–1108.
56González-Gallego, J, García-Mediavilla, MV, Sánchez-Campos, S, et al. (2010) Fruit polyphenols, immunity and inflammation. Br J Nutr 104, S15–S27.
57Sanderson, P, Elsom, RL, Kirkpatrick, V, et al. (2010) UK food standards agency workshop report: diet and immune function. Br J Nutr 103, 1684–1687.
58Bub, A, Watzl, B, Blockhaus, M, et al. (2003) Fruit juice consumption modulates antioxidative status, immune status and DNA damage. J Nutr Biochem 14, 90–98.
59Abid, S, Khajuria, A, Parvaiz, Q, et al. (2012) Immunomodulatory studies of a bioactive fraction from the fruit of Prunus cerasus in BALB/c mice. Int Immunopharmacol 12, 626–634.